Role of nutrition in pregnancy with phenylketonuria and birth defects

Kimberlee Michals Matalon1, Phyllis B Acosta, Colleen Azen

  • 1Department of Health and Human Performance, University of Houston, Houston, Texas 77204-6020, USA. kmatalon@uh.edu

Pediatrics
|December 5, 2003
PubMed

Insights

Maternal phenylketonuria (PKU) can cause birth defects. Early blood phenylalanine control and adequate nutrition during pregnancy are crucial for preventing microcephaly and congenital heart disease (CHD) in offspring.

Area of Science:

  • Obstetrics and Gynecology
  • Medical Genetics
  • Nutritional Science

Background:

  • Maternal phenylketonuria (PKU) is characterized by elevated blood phenylalanine (Phe) levels during pregnancy.
  • High maternal Phe levels are associated with significant birth defects, including microcephaly and congenital heart disease (CHD).

Purpose of the Study:

  • To evaluate the effectiveness of a phenylalanine-restricted diet in preventing maternal PKU syndrome.
  • To assess the impact of blood Phe levels, maternal weight gain, and nutrient intake on microcephaly and CHD rates in offspring.

Main Methods:

  • A prospective, longitudinal international collaborative study involving 251 pregnancies.
  • Stratification of subjects based on blood Phe control (< or =600 micromol/L vs. >600 micromol/L by 8 weeks gestation).
  • Analysis of nutrient intake, weight gain, and correlation with offspring outcomes.

Main Results:

  • Blood Phe control of < or =600 micromol/L by 8 weeks gestation was achieved by 34.3% of women.
  • Infants born to mothers with Phe levels >600 micromol/L had a significantly higher incidence of microcephaly (92%) and CHD.
  • Poor maternal weight gain (<70% recommended) and inadequate protein intake (<50% recommended) were associated with increased microcephaly and CHD, respectively.

Conclusions:

  • Early and effective blood Phe control during pregnancy is critical for preventing birth defects in maternal PKU.
  • Maintaining normal pregnancy weight gain and ensuring adequate protein and vitamin intake may mitigate risks, even with elevated Phe levels.
  • Optimizing nutrient intake alongside Phe level management is key to reducing microcephaly and CHD rates.
Abstract

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...